Diabetes and Endocrine Diseases
SRI holds significant expertise in diabetes, particularly Type 2 Diabetes, with a proven track record of researching nearly all classes of medications across this therapy area. SRI has also worked on Type 1 Diabetes as well as Type 1.5 (LADA). Our comprehensive approach involves extensive physician and patient research, both qualitative and quantitative, conducted globally. We have also conducted extensive Big Data Analytics in these therapy areas.
SRI delivers tracking studies, conjoint discrete choice analyses, advertising impact assessments, and key opinion leader (KOL) research to inform product strategy and market positioning. Using longitudinal patient data, the team uncovers treatment flows, patient segmentation, and drivers and barriers to usage. Additionally, we provide pricing research and promotion response analysis, helping clients refine their commercial and launch strategies with data-driven insights.
In the broader field of endocrinology, SRI has substantial experience across multiple endocrinological conditions and rare diseases. Our stakeholder engagement spans specialist physicians, KOLs, patients, caregivers, payers, health technology assessors, government agencies, pharmacy benefit managers (PBMs), specialty pharmacists, hospitals, nurse practitioners, and patient advocacy groups across North America, Europe, and Asia. SRI adeptly conducts qualitative and quantitative projects, delivering nuanced insights to support market access, pricing, product positioning, and reimbursement strategies. This multi-stakeholder, multi-regional expertise allows SRI to guide clients through complex endocrine therapy landscapes with a thorough understanding of clinical, commercial, and patient-centered factors.